Novostia successfully implants its TRIFLO Heart Valve Implant in first human patient
Life sciences
24 January 2024
This achievement, part of the PILATUS First-In-Human Clinical study (ClinicalTrials ID: NCT06119607), marks a new era in the field of valve replacement. | © Novostia
Novostia, a Vaud-based medical technology company, has successfully implanted its innovative TRIFLO Heart Valve in a human patient for the first time.
Developed by Novostia, the TRIFLO Heart Valve, a pioneering advancement in cardiac technology, was designed to revolutionize aortic heart valve replacement. It offers substantial improvements in blood flow dynamics and longevity, setting a new standard in the treatment of heart valve diseases. Remarkably, the TRIFLO Heart Valve aims to eliminate the need for lifelong anticoagulation therapy, a major shift in the current treatment paradigm. This development not only reduces the risks associated with prolonged anticoagulation but also addresses issues like noise-induced discomfort, significantly enhancing patients’ quality of life.
The first human implantation of the TRIFLO Heart Valve, conducted in December 2023, was led by Prof. Kęstutis Ručinskas, Head of the Heart and Thoracic Surgery Centre at Vilnius University Hospital Santaros Klinikos in Lithuania. Reflecting on the procedure’s success, Prof. Ručinskas commented: “The successful implantation of the TRIFLO Heart Valve is a significant step forward in aortic valve disease management. Seeing our patients recover fully and thrive post-surgery reinforces the valve’s potential to change the landscape of aortic valve treatment.”
Founded in 2017 in Neuchâtel, a region renowned for its innovative technology and biomedical industries, Novostia has been dedicated to developing this groundbreaking artificial heart valve technology. The successful completion of its Series A financing round, raising EUR 2.5 million, was a crucial step in bringing this innovation closer to patients worldwide.
The TRIFLO Heart Valve is set to make a global impact on cardiovascular health. Novostia anticipates that patients globally will soon benefit from this disruptive technology, offering a new hope and an improved quality of life for individuals suffering from aortic stenosis and/or regurgitation.
